Frederick Scott Robinson

Frederick Scott Robinson

Auto-generated profile, based on publicly available information

Frederick Scott Robinson

Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 June 2018 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
YDYonathan Lissanu Deribe
Yonathan Lissanu Deribe
YSYuting Sun
Yuting Sun
CTChristopher Terranova
Christopher Terranova
FKFatima Khan
Fatima Khan
JMJuan Martinez-Ledesma
Juan Martinez-Ledesma
PFP. Andrew Futreal
P. Andrew Futreal

8 February 2017 in Nature
Verified
Journal Article
Closed access
PDF file
GGGiannicola Genovese
Giannicola Genovese
ACAlessandro Carugo
Alessandro Carugo
JTJames Tepper
James Tepper
FRFrederick Scott Robinson
Frederick Scott Robinson
LLLiren Li
Liren Li
LCLynda Chin
Lynda Chin

29 November 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
GEGloria V Echeverria
Gloria V Echeverria
EPEmily Powell
Emily Powell
SSSahil Seth
Sahil Seth
ZGZhongqi Ge
Zhongqi Ge
ACAlessandro Carugo
Alessandro Carugo
HPHelen Piwnica-Worms
Helen Piwnica-Worms
Most triple negative breast cancers (TNBCs) are aggressively metastatic with a high degree of intra-tumoral heterogeneity (ITH), but how ITH contributes to metastasis is unclear. Here, clonal dynamics during metastasis were studied in vivo using two patient-derived xenograft (PDX) models established from the treatment-naive primary breast tumors of TNBC patients diagnosed with synchronous metastasis. Genomic sequencing and high-complexity barcode-mediated clonal tracking reveal robust alterations in clonal architecture between primary tumors and corresponding metastases. Polyclonal seeding and maintenance of heterogeneous populations of low-abundance subclones is observed in each metastasis. However, lung, liver, and brain metastases are enriched for an identical population of high-abundance subclones, demonstrating that primary tumor clones harbor properties enabling them to seed and thrive in multiple organ sites. Further, clones that dominate multi-organ metastases share a genomic lineage. Thus, intrinsic properties of rare primary tumor subclones enable the seeding and colonization of metastases in secondary organs in these models.

5 October 2020 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
KAKadir C. Akdemir
Kadir C. Akdemir
VLVictoria T. Le
Victoria T. Le
JKJustin M. Kim
Justin M. Kim
SKSarah Killcoyne
Sarah Killcoyne
DKDevin A. King
Devin A. King
PFP. Andrew Futreal
P. Andrew Futreal

1 June 2016 in Cell Reports
Verified
Journal Article
Open access
ACAlessandro Carugo
Alessandro Carugo
GGGiannicola Genovese
Giannicola Genovese
SSSahil Seth
Sahil Seth
LNLuigi Nezi
Luigi Nezi
JRJohnathon Lynn Rose
Johnathon Lynn Rose
GDGiulio Draetta
Giulio Draetta
Current treatment regimens for pancreatic ductal adenocarcinoma (PDAC) yield poor 5-year survival, emphasizing the critical need to identify druggable targets essential for PDAC maintenance. We developed an unbiased and in vivo target discovery approach to identify molecular vulnerabilities in low-passage and patient-derived PDAC xenografts or genetically engineered mouse model-derived allografts. Focusing on epigenetic regulators, we identified WDR5, a core member of the COMPASS histone H3 Lys4 (H3K4) MLL (1-4) methyltransferase complex, as a top tumor maintenance hit required across multiple human and mouse tumors. Mechanistically, WDR5 functions to sustain proper execution of DNA replication in PDAC cells, as previously suggested by replication stress studies involving MLL1, and c-Myc, also found to interact with WDR5. We indeed demonstrate that interaction with c-Myc is critical for this function. By showing that ATR inhibition mimicked the effects of WDR5 suppression, these data provide rationale to test ATR and WDR5 inhibitors for activity in this disease.

1 February 2019 in Cell Reports
Verified
Journal Article
Open access
SSSahil Seth
Sahil Seth
CLChieh-Yuan Li
Chieh-Yuan Li
IHI-Lin Ho
I-Lin Ho
DCDenise Corti
Denise Corti
SLSara Loponte
Sara Loponte
AVAndrea Viale
Andrea Viale
Adaptive drug-resistance mechanisms allow human tumors to evade treatment through selection and expansion of treatment-resistant clones. Here, studying clonal evolution of tumor cells derived from human pancreatic tumors, we demonstrate that in vitro cultures and in vivo tumors are maintained by a common set of tumorigenic cells that can be used to establish clonal replica tumors (CRTs), large cohorts of animals bearing human tumors with identical clonal composition. Using CRTs to conduct quantitative assessments of adaptive responses to therapeutics, we uncovered a multitude of functionally heterogeneous subpopulations of cells with differential degrees of drug sensitivity. High-throughput isolation and deep characterization of unique clonal lineages showed genetic and transcriptomic diversity underlying functionally diverse subpopulations. Molecular annotation of gemcitabine-naive clonal lineages with distinct responses to treatment in the context of CRTs generated signatures that can predict the response to chemotherapy, representing a potential biomarker to stratify patients with pancreatic cancer.